Doctors Without Borders demands transparency from GSK on licensing agreements for preventative HIV treatment
GSK has signed licensed agreements with three companies to manufacture generic versions of its preventative HIV medicine for distribution in lower-income countries but calls for increased transparency is putting pressure on the drugmaker.
British drugmaker and pharmaceutical company GSK has signed three deals with separate companies to allow the manufacturing of generic versions of its HIV prevention medicine, cabotegravir, for use in low-income countries.
In a statement, GSK’s HIV treatment division ViiV Healthcare waived intellectual property rights with voluntary licenses issued to Aurobindo Pharma, Cipla, and Viatris. The licenses will give the rights to distribute generic versions of cabotegravir, which is currently distributed under the brand name Vocabria. Indian-based drugmaker Cipla will also be given rights to manufacture the injections in India, with plans to expand manufacturing to South Africa. The generic drug will be supplied to 90 countries dependent on regulatory approvals and could be available as an injection to lower-income countries as early as 2026. Plans were announced last July 2022 for GSK to partner with a UN-backed healthcare organisation to bring novel HIV therapies faster and earlier to lower-income nations than previous HIV treatments.
Pre-exposure prophylaxis (PrEP) remains the most effective way for an at-risk HIV-negative individual to decrease the risk of potential infection. Until recently, the only available form of PrEP was a once-daily pill, which could undermine patient adherence. An injection once every two months such as cabotegravir would ease this burden and provide a more discreet treatment option.
The 1990s and early 2000s saw the deaths of millions of individuals in Africa during the HIV/AIDS crisis. Treatments readily available in wealthier countries were unavailable for use across the African continent. Medical NGO Médecins Sans Frontières/Doctors Without Borders (MSF) had been in negotiations with ViiV to ensure an adequate supply of the drug to lower-income nations, however, were unable to confirm or meet the demand. There have been calls for the GSK division to provide increased transparency for cabotegravir’s manufacturing and procurement, which have been met with evasive responses from the drugmaker. In a statement for MSF, Helen Bygrave, a chronic disease advisor for MSF’s Access Campaign, stated that “ViiV should be ashamed: it has a lifesaving HIV prevention drug at its fingertips but is failing to ensure there’s enough available for people who need it. They’re providing no transparency as to where currently available supplies of [cabotegravir] are being used.”
A spokesperson for GSK responded on their shared ambition with MSF to enable adequate access to the drug, and would plan to update partners such as MSF in the coming weeks: “We are moving at pace to increase capacity to meet the demand.”
Sources:
1. GSK licenses companies to make cheap copies of HIV prevention drug [Accessed April 4 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-licenses-companies-make-cheap-copies-hiv-prevention-drug-2023-03-30/
2. Pharmaceutical company ViiV must provide transparency on HIV prevention drug [Accessed April 4 2023] https://www.msf.org/pharmaceutical-corporation-viiv-must-provide-transparency-life-saving-hiv-prevention-drug
Related News
-
News Ardena forms partnership with RiboPro to improve mRNA-based therapies
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. -
News Updated: Samsung Biologics to manufacture Pfizer's biosimilars products
Samsung Biologics agrees to use their biocampus Plant 4 for the manufacture of a line of products from Pfizer. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Soft capsule technology: modified pea starch as a vegetal origin alternative to gelatin in capsule shell
The latest soft capsule technology from Roquette using modified pea starch as an alternative to gelatin. -
News Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts. -
News High demand: Vetter expands production capacities and services offered at its Austrian site
Pharma service provider further expands offerings for clinical development and manufacturing -
News Novavax will provide adjuvant Matrix-M for vaccine research with 3-year partnership
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance